Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down3.600 -0.060 (-1.639%)

02/07/2021 10:24

Luye Pharma (02186) submits spin-off of Boan Biotech

[ET Net News Agency, 2 July 2021] Luye Pharma Group Ltd. (02186) said the company has
submitted a proposal to the Stock Exchange to effect the spin-off and separate listing of
Shandong Boan Biotechnology Co., Ltd. (Boan Biotech).
Boan Biotech is a fully integrated biopharmaceutical company established in mainland
China. It specializes in therapeutic antibody development, manufacturing and
commercialization with a focus on oncology, autoimmune, pain, and endocrine diseases. (RC)

Remark: Real time quote last updated: 25/01/2022 10:44
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2022 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.